Plain-English translation of Β·
Phase 3 β Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new investigational drug called given together with osimertinib, an already-approved lung cancer medication. Researchers want to see if adding this new medication to the standard treatment helps patients with advanced non-small cell lung cancer (specifically those with an EGFR mutation) live longer and control their cancer better. The study will test different doses of the new medication to find the safest and most effective combination.
Current treatments for this type of advanced lung cancer help many patients, but the cancer often comes back or stops responding over time. This trial is exploring whether adding the new treatment to standard therapy might improve how well patients respond and how long the benefits last.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you join this trial, you will visit a hospital or clinic regularly for about 6 years to receive the medication and have your health monitored. In the first phase, some participants will receive gradually increasing doses of the new medication combined with the standard drug to find the best dose. In the second phase, all participants will receive the doses found to work best. During your visits, you will have blood tests, imaging scans, and check-ins with your care team to track how well the treatment is working and watch for any side effects.
AI-generated summary from trial data Β· Jun 30, 2026 Β· Not medical advice
United States